Aytu BioPharma(AYTU)

Focus: Aytu BioPharma is a public diagnostics and small-molecule pharmaceutical company headquartered in Denver focused on gastroenterology, infectious diseases, and oncology. The company operates at mid-cap scale with $65M in FY2025 revenue.

Gastroenterology Infectious Diseases Oncology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Aytu BioPharma

AI assessmentNot Hiring

No open roles listed right now. Follow Aytu BioPharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

1 in 5yr

KARBINAL ER

Hiring

0 open

Revenue

$65M

FY2025

Key Products

METADATE CD

Attention Deficit Hyperactivity Disorder

LOE Approaching

Core ADHD asset facing loss of exclusivity with no LOE date disclosed; revenue erosion likely imminent.

Help build intelligence for Aytu BioPharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company with established commercial infrastructure across gastroenterology and ADHD markets
Portfolio of peak-revenue products (Zolpimist, Karbinal ER, Aciphex Sprinkle) providing near-term stability
Phase 3 program in rare disease (Vascular Ehlers-Danlos Syndrome with enzastaurin) offers specialty upside

Watch Out For

Declining revenue trajectory ($107M in FY2024 to $65M in FY2025) signals major headwinds or divestitures
Minimal R&D intensity (4%) and only 7 total active trials indicate limited pipeline depth and innovation capacity
Consistent operating losses ($15.8M in FY2025) and declining cash position ($23M to $20M) raise sustainability concerns

Generated by Claude from Aytu BioPharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Established antihistamine with 4+ years of exclusivity remaining; provides near-term revenue floor.

ZOLPIMIST

Insomnia

Peak6.2yr

Oral spray formulation with 7+ years of exclusivity; competitive but stable sleep market contributor.

ACIPHEX SPRINKLE

Gastroesophageal Reflux Disease, Heartburn, H. pylori

Peak

Sprinkle formulation of established PPI class; pediatric/convenience positioning in crowded GERD market.

Pipeline & Clinical Trials

ProxiScan

Prostate Cancer

N/A

Clinical Trials (1)

NCT02786459Detection and Localization of Carcinoma Using High Resolution Transrectal Imaging - Proof of Concept Study

N/A

Antioxidant

Compare the sORP Rate in Sperm Samples, Obtained by the Mioxsys System, Before and After 2.5 Months Antioxidant Men Supplements Treatment (Fertybiotic Man)

N/A

Clinical Trials (1)

NCT04758260Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men Whose Partners Will Undergo Through an Egg Donation Cycle

N/A

UV Light Treatment

Coronavirus

N/A

Clinical Trials (1)

NCT04572399UVA Light Device to Treat COVID-19

N/A

UVA Light Emitting Catheter

COVID-19 Pneumonia

N/A

Clinical Trials (1)

NCT05166915Respiratory COVID-19: A Randomized, Sham-Controlled Study

N/A

Diagnostic

Male Infertility

N/A

Clinical Trials (1)

NCT02839447A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0

N/A

enzastaurin

Vascular Ehlers-Danlos Syndrome

Phase 3

Clinical Trials (1)

NCT05463679Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.

Phase 3

ADZENYS XR-ODT

Attention Deficit Hyperactivity Disorder

Phase 4

Clinical Trials (1)

NCT07169162ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder

Phase 4

amphetamine extended-release orally disintegrating tablet

Attention Deficit Hyperactivity Disorder

Phase 4